License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Affiliations
Liana Gheorghe
Center of Gastroenterology and Hepatology, Fundeni Clinical Institute, Bucharest, Romania
Speranta Iacob
Center of Gastroenterology and Hepatology, Fundeni Clinical Institute, Bucharest, Romania
Irinel Popescu
Center of General Surgery and Liver Transplantation, Fundeni Clinical Institute, Bucharest, Romania
How to Cite
Living Donor Liver Transplantation and Hepatitis
Abstract
Preliminary results indicate that living donor liver transplantation (LDLT) recipients infected with HCV develop earlier and more severe recurrence than their cadaveric counterparts. The mechanisms underlying this observation are unknown, but could include hepatic regeneration, differences in LDLT recipient demographics, immune homology between donor and recipient, or other factors not previously considered. The optimum clinical approach is to consider LDLT in HCV-infected recipients only as a life-saving procedure and to attempt to erradicate HCV before LT to prevent recurrent infection.